Načítá se...
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
Canagliflozin–metformin is one of the newest combination therapies available for the treatment of type 2 diabetes mellitus (T2DM). Canagliflozin is an inhibitor of the sodium–glucose co-transporter 2 which causes an increase in the urinary excretion of glucose. In the present article, we review the...
Uloženo v:
| Vydáno v: | Diabetes Metab Syndr Obes |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4485795/ https://ncbi.nlm.nih.gov/pubmed/26150733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S69282 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|